Asset Details
Do you wish to reserve the book?
The Business of Anti-Aging Science
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Business of Anti-Aging Science
Do you wish to request the book?
The Business of Anti-Aging Science
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Business of Anti-Aging Science
2017
Overview
Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.
It is increasingly being recognized that directly targeting the aging process, as opposed to individual aging-related diseases or symptoms, is a viable strategy. This is leading to R&D with the ultimate aim of commercializing therapies directed at slowing aging itself.
Some therapeutic approaches – direct-to-consumer nutraceuticals and trial-tested scientific diets – do not require FDA approval, which can significantly reduce their time to market.
To slow the aging process, nonstandard therapies such as blood-based therapies are also being tried.
Big-data approaches are being harnessed in an attempt to build models of healthy aging.
Approaches are increasingly coming directly from aging results in model organisms.
